Bavarian gains after mpox order brings guidance to top end
(Bloomberg) — Bavarian Nordic A/S (BAVA.CO) shares rose after the Danish supplier of a key vaccine against mpox said it will attain the top end of its full-year guidance following an order for the jabs from Europe.
Most Read from Bloomberg
Chicago's Migrant Surge Is Stirring Trouble for Democrats in DNC Host City
UK Transport Minister Clears Path for More 20mph Speed Zones
With Self-Driving Vans, Hamburg Tries to Make Microtransit Work
It’s now got enough contracts with governments, including the US, to reach aggregate revenue of about 5.3 billion Danish kroner ($790 million) this year amid the worst outbreak of mpox to date in Africa.
Chief Executive Officer Paul Chaplin told Bloomberg TV in an interview his company is ready to ramp up production to “ship significant doses” to Africa and has “a huge capacity for the remainder of this year,” but is still lacking the orders.
Listen to the Here’s Why podcast on Apple, Spotify or anywhere you listen.
The stock advanced as much as 13% at the start of trading in Copenhagen on Thursday, extending its year-to-date gains to more than 55%.
Bavarian’s mpox vaccine is the only inoculation for the deadly virus approved by both US and European Union regulators.
Bavarian on Thursday said second-quarter sales of its mpox and smallpox vaccine, marketed as Jynneos in the US, reached 680 million kroner. It expects that amount to reach 3 billion kroner for the full year, which is now already mostly covered by large contracts placed by government entities.
Bavarian reported second-quarter revenue of 1.43 billion kroner, topping estimates.
The contract unveiled on Wednesday is for 440,000 doses of the smallpox/mpox vaccine from an undisclosed European country. It will help Bavarian generate a 2024 total 1.35 billion kroner in earnings before interest, tax, depreciation and amortization. The order was anticipated and won’t impact its remaining vaccine capacity for the year, the company said.
The WHO last week said that the mpox outbreak represents a global health emergency — a second such declaration since 2022, with the deadly virus spreading quickly across Africa. The growing incidence of the new strain of mpox from Democratic Republic of Congo means there have been almost 19,000 cases on the continent since the beginning of the year.
“We have to make decisions very, very soon,” Chaplin said in the TV interview. “So that’s why we’re talking with all the stakeholders and really trying to understand what the real demand is going to be. But most likely we will have to start ramping up production and moving over to our mpox vaccine very shortly.”
Chaplin also said Bavarian is in talks with seven different companies in Africa to move some of the manufacturing to the continent, as local production “is always the key” to handle a developing outbreak.
The outbreak is also likely to lead to “sporadic” imported cases in Europe, the European Centre for Disease Prevention and Control Director Pamela Rendi-Wagner said on Bloomberg TV Wednesday, adding that EU member states all need to be prepared.
Bavarian’s vaccine was approved for mpox in the US in 2019 and in Europe in 2022. It was developed after the 9/11 attacks, when the US decided to stock up on vaccines for smallpox as part of its anti-terrorism program. The company now wants to extend formal approval in Europe to include adolescents and plans to study efficacy in kids.
—With assistance from Christian Wienberg, Naomi Kresge, Kriti Gupta and Guy Johnson.
(Updates with shares, earnings from first paragraph. Adds CEO comments from third paragraph)
Most Read from Bloomberg Businessweek
‘I’m So Scared’: NFL Players on How Betting Changes the Sport
Covid Hobbled a Profitable Bond Trade. High Interest Rates Are Reviving It
?2024 Bloomberg L.P.